Below are the most recent publications written about "Morpholines" by people in Profiles.
-
Ailani J, Gandhi P, Lalla A, Halker Singh R, McAllister P, Smith JH, Dabruzzo B, Chalermpalanupap N, Kelton K, Nahas SJ. Cost per treatment responder analysis of atogepant compared to rimegepant for the preventive treatment of episodic migraine. Headache. 2024 Nov-Dec; 64(10):1253-1263.
-
Adalbert JR, Syal A, Varshney K, George B, Hom J, Ilyas AM. The prescription drug monitoring program in a multifactorial approach to the opioid crisis: PDMP data, Pennsylvania, 2016-2020. BMC Health Serv Res. 2023 Apr 13; 23(1):364.
-
Singh PM, Borle A, Rewari V, Makkar JK, Trikha A, Sinha AC, Goudra B. Aprepitant for postoperative nausea and vomiting: a systematic review and meta-analysis. Postgrad Med J. 2016 Feb; 92(1084):87-98.
-
Gibson CM, Mehran R, Bode C, Halperin J, Verheugt F, Wildgoose P, van Eickels M, Lip GY, Cohen M, Husted S, Peterson E, Fox K. An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI). Am Heart J. 2015 Apr; 169(4):472-8.e5.
-
Ezekowitz MD, Kent AP. Novel anticoagulants eliminate the need for left atrial appendage exclusion devices. Circulation. 2014 Oct 21; 130(17):1505-14.
-
Cappato R, Ezekowitz MD, Klein AL, Camm AJ, Ma CS, Le Heuzey JY, Talajic M, Scanavacca M, Vardas PE, Kirchhof P, Hemmrich M, Lanius V, Meng IL, Wildgoose P, van Eickels M, Hohnloser SH. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. Eur Heart J. 2014 Dec 14; 35(47):3346-55.
-
Brailoiu GC, Deliu E, Marcu J, Hoffman NE, Console-Bram L, Zhao P, Madesh M, Abood ME, Brailoiu E. Differential activation of intracellular versus plasmalemmal CB2 cannabinoid receptors. Biochemistry. 2014 Aug 05; 53(30):4990-9.
-
Ezekowitz MD, Spahr J, Ghosh P, Corelli K. Stroke prevention in atrial fibrillation: established oral anticoagulants versus novel anticoagulants-translating clinical trial data into practice. J Interv Card Electrophysiol. 2014 Sep; 40(3):261-8.
-
Wachsberger PR, Lawrence YR, Liu Y, Rice B, Feo N, Leiby B, Dicker AP. Hsp90 inhibition enhances PI-3 kinase inhibition and radiosensitivity in glioblastoma. J Cancer Res Clin Oncol. 2014 Apr; 140(4):573-82.
-
Sinha AC, Singh PM, Williams NW, Ochroch EA, Goudra BG. Aprepitant's prophylactic efficacy in decreasing postoperative nausea and vomiting in morbidly obese patients undergoing bariatric surgery. Obes Surg. 2014 Feb; 24(2):225-31.